Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid

BMC Cancer

Arnaud Scherpereel³  Bogdan Dragos Grigoriu⁷  Marc Noppen¹  Thomas Gey²  Bachar Chahine²  Simon Baldacci²  Jacques Trauet⁵  Marie-Christine Copin⁶  Jean-Paul Dessaint⁵  Henri Porte⁴  Myriam Labalette⁵ 

[1] Pulmonary Department, UZ Brussel, 101 Laarbeeklaan, Brussels, Belgium

[2] Pulmonary and Thoracic Oncology Department, Hopital Calmette, CHRU de Lille, Lille cedex 59037, France

[3] Faculte de Medecine Henri Warembourg, University of Lille Nord de France, Lille, France

[4] Department of Thoracic Surgery, CHRU de Lille, Lille, France

[5] Department of Immunology, EA 2686, IFR114, CHRU de Lille, Lille, France

[6] Department of Pathology, CHRU de Lille, Lille, France

[7] Department of Pulmonary Diseases, University of Medicine and Pharmacy, Iasi, Romania

关键词: Lymphocytes;    Immunity;    Mesothelioma;    Tumor;    Effusion;    Pleura;   

Others  :  1079666
DOI  :  10.1186/1471-2407-13-324

 received in 2013-02-08, accepted in 2013-06-28,  发布年份 2013

【 摘 要 】

Background

Malignant pleural effusions (MPE) are a common and fatal complication in cancers including lung or breast cancers, or malignant pleural mesothelioma (MPM). MPE animal models and immunotherapy trials in MPM patients previously suggested defects of the cellular immunity in MPE. However only few observational studies of the immune response were done in MPM patients, using questionable control groups (transudate…).

Methods

We compared T cell populations evaluated by flow cytometry from blood and pleural effusion of untreated patients with MPM (n = 58), pleural metastasis of adenocarcinoma (n = 30) or with benign pleural lesions associated with asbestos exposure (n = 23). Blood and pleural fluid were also obtained from healthy subjects, providing normal values for T cell populations.

Results

Blood CD4⁺ or CD8⁺ T cells percentages were similar in all groups of patients or healthy subjects. Whereas pleural fluid from healthy controls contained mainly CD8⁺ T cells, benign or malignant pleural effusions included mainly CD4⁺ T cells. Effector memory T cells were the main T cell subpopulation in pleural fluid from healthy subjects. In contrast, there was a striking and selective recruitment of central memory CD4+ T cells in MPE, but not of effector cells CD8⁺ T cells or NK cells in the pleural fluid as one would expect in order to obtain an efficient immune response.

Conclusions

Comparing for the first time MPE to pleural fluid from healthy subjects, we found a local defect in recruiting effector CD8⁺ T cells, which may be involved in the escape of tumor cells from immune response. Further studies are needed to characterize which subtypes of effector CD8+ T cells are involved, opening prospects for cell therapy in MPE and MPM.

【 授权许可】

   
2013 Scherpereel et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Sahn S: Malignant pleural effusions. In Pleural disease. Edited by Bouros D. London: Informa Healthcare; 2004:411-438.
• [2]Scherpereel A, et al.: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010, 35(3):479-495.
• [3]Robinson BW, Robinson C, Lake RA: Localised spontaneous regression in mesothelioma – possible immunological mechanism. Lung Cancer 2001, 32(2):197-201.
• [4]Astoul P, et al.: Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998, 83(10):2099-2104.
• [5]Boutin C, et al.: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994, 74(9):2460-2467.
• [6]Sebastian M, et al.: Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother 2009, 32(2):195-202.
• [7]Hegmans JP, et al.: Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 2005, 171(10):1168-1177.
• [8]Hegmans JP, et al.: Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181(12):1383-1390.
• [9]Sterman DH, et al.: A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011, 184(12):1395-1399.
• [10]Gregoire M: Dendritic cell vaccination as a treatment modality for mesothelioma. Expert Rev Respir Med 2010, 4(3):311-314.
• [11]Antony VB, et al.: Recruitment of inflammatory cells to the pleural space. Chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993, 151(12):7216-7223.
• [12]Sallusto F, Lanzavecchia A: Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 2009, 39(8):2076-2082.
• [13]Sallusto F, et al.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401(6754):708-712.
• [14]Wherry EJ, et al.: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4(3):225-234.
• [15]Harari A, et al.: Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005, 174(2):1037-1045.
• [16]Roberts AD, Woodland DL: Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol 2004, 172(11):6533-6537.
• [17]Klebanoff CA, Gattinoni L, Restifo NP: CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006, 211:214-224.
• [18]Okamoto M, et al.: T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 2005, 128(6):4030-4035.
• [19]Aguiar LM, et al.: Malignant and tuberculous pleural effusions: immunophenotypic cellular characterization. Clinics (Sao Paulo) 2008, 63(5):637-644.
• [20]Klimiuk J, et al.: Lymphocyte and lymphocyte subsets in pleural fluid--comparison of malignant and non-malignant disorders. Pol Arch Med Wewn 2004, 111(3):291-296.
• [21]Scherpereel A, et al.: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006, 173(10):1155-1160.
• [22]Grigoriu BD, et al.: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13(10):2928-2935.
• [23]Noppen M, et al.: Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000, 162:1023-1026.
• [24]Conover WJ, Iman RL: Analysis of covariance using the rank transformation. Biometrics 1982, 38(3):715-724.
• [25]Baecher-Allan C, et al.: CD4 + CD25high Regulatory cells in human peripheral blood. J Immunol 2001, 167(3):1245-1253.
• [26]Saule P, et al.: Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4+ versus effector memory and terminally differentiated memory cells in CD8+ compartment. Mech Ageing Dev 2006, 127:274-281.
• [27]Atanackovic D, et al.: Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clin Cancer Res 2004, 10(8):2600-2608.
• [28]Prado-Garcia H, et al.: Effector, memory and naive CD8+ T cells in peripheral blood and pleural effusion from lung adenocarcinoma patients. Lung Cancer 2005, 47(3):361-371.
• [29]Khalil RY, Khalil MM: Flow cytometric study of T-cell subsets in lymphocytic pleural effusions. Cytometry 1997, 30(4):204-205.
• [30]Szyllo K, et al.: The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis. Mediators Inflamm 2003, 12(3):131-138.
• [31]Lucivero G, Pierucci G, Bonomo L: Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J 1988, 1(4):337-340.
• [32]San Jose ME, et al.: Lymphocyte populations in tuberculous pleural effusions. Ann Clin Biochem 1999, 36(Pt 4):492-500.
• [33]Jassar AS, et al.: Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005, 65(24):11752-11761.
• [34]Odaka M, et al.: Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001, 61(16):6201-6212.
• [35]Zhang L, et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213.
• [36]Shankaran V, et al.: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410(6832):1107-1111.
• [37]Balkwill F: Chemokine biology in cancer. Semin Immunol 2003, 15(1):49-55.
• [38]Atanackovic D, et al.: The local cytokine and chemokine milieu within malignant effusions. Tumour Biol 2008, 29(2):93-104.
• [39]Hoffmann TK, et al.: Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002, 8(8):2553-2562.
• [40]Lockhart DC, et al.: Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001, 129(6):749-756.
• [41]Oka M, et al.: The characterization of peritoneal and pleural exudate cells from malignant effusions. Surg Today 1993, 23(6):500-503.
• [42]Sikora J, Zeromski J: Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions. Folia Histochem Cytobiol 2002, 40(4):347-351.
• [43]Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999, 48(7):346-352.
• [44]Chen YQ, et al.: CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion. Am J Respir Crit Care 2005, 172(11):1434-1439.
• [45]Delong P, et al.: Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005, 4(3):342-346.
• [46]Li H, et al.: Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother 2011, 60(11):1587-1596.
• [47]Qin XJ, et al.: CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009, 15(7):2231-2237.
• [48]Hegmans JP, et al.: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27(6):1086-1095.
• [49]Stathopoulos GT, et al.: A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008, 100(20):1464-1476.
• [50]Chen YM, et al.: Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996, 110(2):433-436.
• [51]Colucci F, Di Santo JP, Leibson PJ: Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol 2002, 3(9):807-813.
• [52]Loza MJ, et al.: Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 2002, 99(4):1273-1281.
• [53]Yamada N, et al.: CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010, 59(10):1543-1549.
• [54]Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP: Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer 2012, 12:580. BioMed Central Full Text
• [55]Thomas A, Hassan R: Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012, 13:e301-e310.